News
Nerviano Medical Sciences Srl partecipa alla European Biotech Week 2023 / Nerviano Medical Sciences Srl participates in the European Biotech Week 2023
La EBW è una settimana di eventi e incontri in tutta Europa per raccontare le biotecnologie nei diversi settori di applicazione ad un pubblico vasto e diversificato, sottolineando il ruolo chiave che queste tecnologie hanno nel migliorare la qualità della vita di tutti noi.
(Click the title for the complete article)
Nerviano Medical Sciences S.r.l. announces preclinical data on NMS-P945, its novel proprietary payload-linker for ADC generation, published in Molecular Cancer Therapeutics
Nerviano, September 20, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A. and a clinical stage biotech, discovering and developing innovative therapies for the treatment of cancer, today announces the publication of preclinical data on NMS-P945 (link to article), its novel protease-cleavable thienoduocarmycin derivative payload-linker, with DNA damaging properties, in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
(Click the title for the complete article)
SIMIS Srl Announces Nomination of Laurent Contaut as the new CEO of SIMIS, a company part of NMS Group
SIMIS Srl (SIMIS), a NMS Group company, is pleased to announce the appointment of Laurent Contaut as the new Chief Executive Officer (CEO) of the organization, effective immediately. The appointment of Laurent comes at an exciting time for SIMIS, as the company continues to expand its services and drive innovation in the pharmaceutical and biotech industries.
(Click the title for the complete article)
Nerviano Medical Sciences S.r.l. names Alberto Ocana, PhD, as Global Clinical Lead
NMS Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that Alberto Ocana PhD, has joined the Global Clinical Development Team as Global Clinical Lead, effective immediately. In this pivotal role, Alberto will spearhead the company’s efforts to drive innovation, enhance patient outcomes, and strengthen our global partnerships.
(Click the title for the complete article)
Nerviano Medical Sciences Announces Enhanced US Executive Team: Terrence West, MBA, Expands Role as Chief Operating Officer
NERVIANO, IT and BOSTON, Mass., August 1, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the expansion of and transition in its executive team of its wholly owned U.S. subsidiary (Nerviano Medical Sciences, Inc./ NMS-US) in Boston. Terrence West, MBA, the company’s New Business, Virtual CEO has been appointed to the newly created position of Chief Operating Officer, effective immediately, to further drive the growth of NMS-US while continuing to oversee the strategic positioning of NMS-173, its IDH1/IDH2 Inhibitor Asset.
(Click the title for the complete article)
Nerviano Medical Sciences Announces FDA Clearance of Investigational New Drug (IND) for NMS-03592088 in positive Relapsed or Refractory Acute Myeloid Leukemia
Nerviano 22 June 2023_Nerviano Medical Sciences Srl (NMS), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to announce the FDA Clearance of Investigational New Drug (IND) Application for NMS-03592088 (NMS-088), a novel, potent FLT3 inhibitor.
(Click the title for the complete article)
Nerviano Medical Sciences Announces Licensing of Linker-Payload Technology to Solve Therapeutics to Develop and Commercialize Novel Antibody-Drug Conjugates
Nerviano Medical Sciences S.r.l. announced signing of a license agreement and right of option with Solve Therapeutics, Inc. (SolveTx) to develop and commercialize novel antibody-drug conjugates (ADCs) for up to four cancer targets selected by SolveTx.
(Click the title for the complete article)
Nerviano Medical Sciences S.r.l. to Present MPSA-153-001 at ASCO 2023: Slide deck, Poster and Video Preview
Nerviano, 26 May 2023 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, published a poster today, describing the currently enrolling phase II part of the trial MPSA-153-001, will be presented at the upcoming ASCO Annual Meeting which will be held June 2-6, 2023 at the McCormick Place, Chicago, IL.
(Click the title for the complete article)
Nerviano Medical Sciences Appointed Paramjit Kaur, PhD to Accelerate PERK/GCN2 Inhibitor Asset Development
NERVIANO, May 17th 2023 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Paramjit Kaur, PhD has joined the Global Asset Leadership Team to lead the strategy and the development of clinical PERK/GCN2 asset currently in phase 1.
(Click the title for the complete article)
Nerviano Medical Sciences S.r.l. to Present at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Nerviano, 15 May 2023 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that a poster, describing the currently enrolling phase II part of the trial M
PSA-153-001, will be presented at the upcoming ASCO Annual Meeting which will be held June 2-6, 2023 at the McCormick Place, Chicago, IL.
(Click the title for the complete article)
Welcome and Check out our new motion picture!